| Literature DB >> 34070285 |
Prakrati Acharya1, Chirag Acharya2, Charat Thongprayoon3, Panupong Hansrivijit4, Swetha R Kanduri5, Karthik Kovvuru5, Juan Medaura6, Pradeep Vaitla6, Desiree F Garcia Anton6, Poemlarp Mekraksakit7, Pattharawin Pattharanitima8, Tarun Bathini9, Wisit Cheungpasitporn3.
Abstract
Very-low-carbohydrate diets or ketogenic diets are frequently used for weight loss in adults and as a therapy for epilepsy in children. The incidence and characteristics of kidney stones in patients on ketogenic diets are not well studied.Entities:
Keywords: epidemiology; ketogenic diet; kidney stones; meta-analysis; nephrolithiasis; systematic review
Year: 2021 PMID: 34070285 PMCID: PMC8161846 DOI: 10.3390/diseases9020039
Source DB: PubMed Journal: Diseases ISSN: 2079-9721
Figure 1The literature retrieval, review, and selection process.
Characteristics of studies included in this systematic review.
| Reference | Description of | Total | Mean Age of Included | Mean | No. of Patients with Kidney Stones | % of | 24 h Urine Study |
|---|---|---|---|---|---|---|---|
| Holler A. et al. [ | Classical KD (16), Modified Atkins diet (MAD) (14) | 31 | Median 5.5, mean 5.5 (0.1–15.7 Y) | N/A | 0 | 0 | Hypercalciuria in 12/22 |
| Rener et al. [ | 2.5:1 to 45/3/20201 | 15 | <3 Y | Average 13 M (4–16 M) | 1 | 6.60% | N/A |
| Attar H. et al. [ | Modified Atkins diet | 13 | 23–72 Y | Range 1–21 M | 1 | 7.69% | N/A |
| Felix et al. [ | Modified Atkins diet | 5 | 6–12 Y | 4 M | 0 | 0 | 1 had hypercalciuria |
| Lapp et al. [ | KGD in 7 and Modified Atkins diet in 19 | 26 | >18 Y | N/A | 4 | 15% | N/A |
| Nerurkar et al. [ | KGD | 17 | <3 Y | N/A | 1 | 5.88% | N/A |
| Nangia et al. [ | KGD | 59 | 4.5 Y (range 0.2–22 Y) | Mean 2 Y (range 0–5.5 Y) | 3 | 5% | N/A |
| Gainza et al. [ | KGD | 41 | 4.7 Y (range 1–13 Y) | Mean 5.79 Y (3–10.6) | 3 | 7.10% | Hypercalciuria in 11 (26.2%) |
| Mak et al. [ | KGD (MCT oil diet) | 13 | 7.3 Y | N/A | 1 | 7.70% | Increase Ca/Cr ratio in 1 patient |
| Furth et al. [ | N/A | 112 | 5 Y | N/A | 6 | 5.30% | Elevated Ca/Cr ratio |
| Rios et al. [ | 4:1 (1.5:1–4.5:1) KGD | 22 | Range 1–19 Y (min age 18 M) | 25 M (1–54 M) | 2 | 9.09% | N/A |
| Sharma et al. [ | 3:1 KGD in <18 M, 4:1 KGD in >18 M | 23 | (range 6 M–5 Y) | N/A | 1 | 3.70% | Elevated Ca/Cr ratio |
| Kang et al. [ | 3:1 KGD | 40 | Median ± IQR- 15 ± 13.0 (range 6–60 M) | N/A | 2 | 5.00% | N/A |
| Wibisono et al. [ | Classic KGD, MCT diet, Modified Atkins diet | 48 | 3.8 Y (range 2.3–7 Y) | Range 1–14 Y | 2 | 4.00% | N/A |
| Simm et al. [ | 4:1 to 2:1 KGD | 29 | 6.4 Y (range 3.3–17.8 Y) | Mean 2.1 Y (range 0.5–6.5 Y) | 1 | N/A | N/A |
| Guzel et al. [ | Olive oil-based KGD | 389 | Median 4.0 (2–7)Y | 12 M | 12 | 3% | N/A |
| Hassan et al. [ | Classic 4:1 KGD (49 of 52 pts), rest with modified diet supplemented by MCT oil | 52 | 5 Y, 6 M ± 3 Y, 4 M | N/A | 1 | 1.90% | Increased calcium oxide in urine |
| Takeoka et al. [ | 3:1 to 4.1 KGD + Topiramate | 14 | Mean age 4.7 Y | N/A | 0 | 0% | N/A |
| Kossoff et al. [ | KGD (older children on 4:1 diet and younger on 3:1) without carbonic anhydrase inhibitors | 221 | 5.1 Y (SD 4.5, range 16.5 Y) | N/A | 15 | 6.70% | N/A |
| Kossoff et al. [ | KGD (older children on 4:1 diet and younger on 3:1) with topiramate or zonisamide | 80 | 4.8 Y (SD 2.4, range 6.5 Y) | N/A | 5 | 6.30% | N/A |
| Kossoff et al. [ | 4:1 KGD in 9, 3.5:1 in 1 and 3:1 in 13 | 23 | 1.1 Y (range 0.5–24 M) | N/A | 2 | 8.60% | N/A |
| Kang et al. [ | 4:1 KGD | 129 | 64.9 (±59.3) M | 12.0 (±10.1) M | 4 | 3.10% | N/A |
| Mackay et al. [ | N/A | 26 | Median age 6.1 Y (range 2.3–13.2) | N/A | 0 | 0% | Increased urine calcium in 8% |
| Groesbeck et al. [ | 4:1 KGD in 19, 3:1 KGD in 9 | 28 | 3 Y 9 M (range 6 M–13 Y 6 M) | 7 Y 9 M | 7 | 25% | Increase Ca Cr ratio in 14 pts |
| Sampath et al. [ | 3:1 (56%) or 4:1 KGD | 195 | Median 3 Y (0.5–15 Y) | Median 12 M (range 1–72 M) | 13 | 7% | N/A |
| Raimann et al. [ | 4:1 in 16, 3.5:1 in 3 and 3:1 in 2 + Calcium and MV supplement | 21 | 6.2 Y (range 6 M–17 Y) | 15 pt completed 1 Y of KGD 2.6 Y (1–6.3 Y) | 2 | 10% | Hypercalciuria in both stone formers |
| Caraballo et al. [ | N/A | 140 | 5 Y (range 1–18 Y | 3.5 Y (range 1–20 Y) | 6 | 4.28% | N/A |
| Dressler et al. [ | 4:1 in 36, 3:1 in 53, 3.5:1 in 6, 2.5:1 in 17, 2:1 in 3 | 115 | 2.86 ± 3.1 (min 0.0–max 16.8) | N/A | 4 | 3.40% | N/A |
| Hallbook et al. [ | N/A | 290 | 5.3 (0.6–18.6) | 2 Y | 7 | N/A | N/A |
| Khoo et al. [ | 4:1 in 12, 3:1 in 11, 2:1 in 3, MAD in 4 | 30 | 6.8 Y (8 M to 17 Y) | 8 M (range 7 days to 6 Y) | 4 | 13% | N/A |
| Lim et al. [ | N/A | 204 | 4.8 Y (range 0.3–33.9 Y) | Median 17 M (95% CI 9–24 M) | 2 | 0.98% | N/A |
| McNally et al. [ | 3:1 or 4;1 KGD | 195 (KGD + | 4.3 Y in | 15.6 (13.1) | 13 | 6.70% | N/A |
| Park et al. [ | N/A | 16 | Age range (0.1–40 Y) | N/A | 1 | 6.25% | N/A |
| Draaisma et al. [ | Classic KGD (67.6%), MCT diet (2.9%), MAD (19.1%) or LGIT (7.4%), other (1.5%) | 68 | 5.7 ± 4.3 Y | 25.6 ± 24.8 M | 6 | 8.80% | N/A |
| Roehhl et al. [ | Modified KGD | 55 | Mean 38 Y (range 17–70 Y) | N/A | 0 | 0% | N/A |
| Lambrechts et al. [ | MCT diet and Classic KGD | 26 | 7 Y | 0 | 0 | N/A | N/A |
Abbreviations: KGD—ketogenic diet, MCT—medium chain triglyceride, F/H—family history, Y—years, M—months, pts—patients, Ca—calcium, Cr—creatinine, MV—multivitamin, K citrate—potassium citrate, RR—relative risk, NR—not recorded, gp—group, LGIT—low glycemic index treatment, MAD—modified Atkin’s diet.
Definitions and reported adverse effects observed in ketogenic diets in different studies.
| Author | Different Types of | Side Effects/Complication of Ketogenic Diet besides Renal Stones |
|---|---|---|
| Holler A. et al. [ | Classical KGD and MAD | Constipation, increased bromine level (3.2%) |
| Rener et al. [ | KGD 2.5:1 to 4:1 | Vomiting |
| Attar H. et al. [ | MAD | NR |
| Felix et al. [ | MAD | Weight loss, hyperlipidemia |
| Lapp et al. [ | KGD, MAD | Gallstones (3.8%), hyperlipidemia (3.8%) |
| Nerurkar et al. [ | KGD not specified | Constipation (57%) |
| Nangia et al. [ | KGD 3:1 to 4:1 | Constipation (39%), acidosis (21%), nausea/emesis (14%), increased seizures (7%). |
| Gainza et al. [ | KGD not specified | Osteopenia (38.1%), severe metabolic acidosis (9.5%), recurrent pneumonia (21.4%), neutropenia (0.5%), fatty liver (0.1%), easy bruising (4.8%) |
| Mak et al. [ | KGD—Protein + carb (<19%) of caloric requirements | Weight loss (46%), diarrhea (38%), bad temper (7.6%), abdominal cramps (15%), nausea (15%), bad body smell (7.6%) |
| Furth et al. [ | NR | |
| Rios et al. [ | KGD 4:1 (1.5:1 to 4.5:1) | Nausea and vomiting (26.3%), hypercholesterolemia (64.7%), anorexia (31.8%), constipation (40.9%), symptomatic acidosis (9.09%), carnitine deficiency (9.09%) |
| Sharma et al. [ | Classical KGD 3:1 or 4:1 | Vomiting (75%), asymptomatic hypocalcemia, Constipation (75%), weight loss, hypoalbuminemia |
| Kang et al. [ | Classical KGD 4:1 | Dehydration, GI discomfort, hyperlipidemia, hyperuricemia, symptomatic hypoglycemia, lipoid aspiration pneumonia, hypoproteinemia, hypomagnesemia, repeated hyponatremia |
| Wibisono et al. [ | Classical KGD, MCT, MAD | Constipation, hypertriglyceridemia, hypercholesterolemia, diarrhea, lethargy, iron deficiency, GERD, vomiting, hypoglycemia |
| Simm et al. [ | KGD 2:1 to 4:1 | Osteopenia, fracture |
| Guzel et al. [ | KGD 2.5:1 and 4:1 | Hyperlipidemia (50.8%), selenium deficiency (26.9%), constipation (26.2%), sleep disturbances (20%), hyperuricemia (3%), hepatic effects (2.6%), hypoproteinemia (2.6%), hypoglycemia(1.5%) |
| Hassan et al. [ | Classic 4:1 KGD or MCT diet | Constipation (85%), gall bladder stone (1.9%), hyponatremia (1.9%) |
| Takeoka et al. [ | KGD not specified | Nausea/vomiting (7%), irritability (7%), lethargy (21%), sedation (14%) |
| Kossoff et al. [ | KGD 3:1 to 4:1 | NR |
| Kossoff et al. [ | KGD 3:1 to 4:1 | Sedation (27%), rash, irritability |
| Kossoff et al. [ | KGD 3:1 to 4:1 | Severe GERD (13%), hip dislocation (0.4%) |
| Kang et al. [ | Dehydration, GI discomfort, hyperlipidemia, hyperuricemia, hypoglycemia | |
| Mackay et al. [ | Classical KGD 3:1 to 4.2:1 | Asymptomatic hypoglycemia (24%), poor linear growth (20%), hyperlipidemia (16%), vomiting (12%), hypocarnitinemia (8%), hypercalciuria (8%), constipation (8%), osteopenia (4%), pancreatitis (4%), Diarrhea (4%) |
| Groesbeck et al. [ | 60.7% on classical KDT | Fractures (21.4%), hyperlipidemia (7%), constipation (53%) |
| Sampath et al. [ | KGD 3:1 (56%) or 4:1 | NR |
| Raimann et al. [ | KGD 4:1 (3 pts 3.5:1 2 pts 3:1) | Hypercholesterolemia 64% (at 12 months) 15% (at 18 months), growth retardation |
| Caraballo et al. [ | KGD | GI side effects (30.5%), hyperlipidemia (9.7%), weight gain (2.3%), hypocarnitinemia (3.7%), hypercalciuria (6.9%), hypoglycemia (5.5%), dehydration (6.4%) |
| Dressler et al. [ | KGD 3:1, 4:1 or 2.5:1 | Carnitine deficiency (13%), growth deficit (5.2%), weight gain (1.7%), hypertriglyceridemia (29.5%), hypercholesterolemia (10.4%) |
| Hallbook et al. [ | KGD 3:1 or 4:1 ratio | Hyperlipidemia (6%), bone fractures (0.9%) |
| Khoo et al. [ | Classical KGD (81.2%), MAD (18.75%) | Constipation (43%), hunger (23%), excessive weight gain or loss (20%), vomiting (10%), hyperuricemia (30%), hypocalcemia (20%) |
| Lim et al. [ | NR | GI side effects (nausea, vomiting, and constipation), Inadequate weight gain or significant weight loss, ketoacidosis, hepatotoxicity, renal dysfunction, sinus tachycardia, osteoporosis |
| McNally et al. [ | KGD unspecified | NR |
| Park et al. [ | KGD 4:1 (87.5%), KGD 3:1 (12.5%) | Regurgitation, constipation, aspiration, hypertriglyceridemia, hypoproteinemia, nausea, vomiting |
| Draaisma et al. [ | Classic KGD (67.6%), MCT diet (2.9%) | Decrease in BMD 0.22 Z-score/year |
| Roehhl et al. [ | Modified ketogenic diet | Constipation (9%) |
| Lambrechts et al. [ | KGD | GI side effects (30%) |
Abbreviations: KGD—ketogenic diet; MAD—modified Atkins diet; MCT—medium chain triglyceride diet; NR—non-report; LGID—low glycemic index diet.
Figure 2Pooled estimated incidence of kidney stones.
Figure 3Pooled estimated incidence of kidney stones by patient population.